CJC-1295 (no DAC) vs Tesamorelin
Both CJC-1295 (no DAC) and Tesamorelin are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
CJC-1295 (no DAC)
Evidence BModified Growth Hormone Releasing Factor 1-29
A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
View full CJC-1295 (no DAC) profile →Tesamorelin
Evidence ATesamorelin (Egrifta)
An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
View full Tesamorelin profile →Side-by-Side
| Attribute | CJC-1295 (no DAC) | Tesamorelin |
|---|---|---|
| Evidence Grade | B | A |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | FDA-approved for HIV-associated lipodystrophy |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | 2 mg daily (subcutaneous) |
| Clinics Indexed | 156 | 178 |
| Categories | growth-hormone, anti-aging, recovery | growth-hormone, fat-loss |
Key reported benefits — CJC-1295 (no DAC)
- ✓Growth hormone release
- ✓Fat loss
- ✓Improved sleep
- ✓Muscle recovery
Key reported benefits — Tesamorelin
- ✓Visceral fat reduction
- ✓Natural GH stimulation
- ✓Cognitive benefit
- ✓Lean mass
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.